Skip to main content
Clinical Trials/NCT00538928
NCT00538928
Completed
Not Applicable

Extrapulmonary Interventional Ventilatory Support for Lung Protection in Severe Acute Respiratory Distress - a Prospective Randomized Multi Centre Study

University of Regensburg1 site in 1 country120 target enrollmentSeptember 2007

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Respiratory Distress Syndrome
Sponsor
University of Regensburg
Enrollment
120
Locations
1
Primary Endpoint
Ventilator free days within 28 days after enrollment
Status
Completed
Last Updated
15 years ago

Overview

Brief Summary

A prospective, randomized study will be performed investigating the effects of a pumpless extracorporeal interventional lung assist [iLA] on the implementation of a lung-protective ventilatory strategy in patients with acute respiratory distress syndrome [ARDS] with a PaO2/FiO2 ratio < 200. The duration of ventilation, intensive care and hospital stay and in-hospital mortality will be investigated.

Detailed Description

Evaluation group: Implantation of the iLA - adaptation of the ventilation strategy, explantation of the iLA after corresponding improvement (see treatment plan for details) - weaning from the ventilation and extubation according to specified criteria. Control group: Ventilation strategy based on the concept of lung-protective ventilation without extracorporeal support, weaning from the ventilation and extubation according to specified criteria (see treatment plan for details).

Registry
clinicaltrials.gov
Start Date
September 2007
End Date
January 2011
Last Updated
15 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • The trial subjects are patients aged 18 years or older who have developed severe ARDS. Following the American-European Consensus Conference on ARDS, severe ARDS is defined as an oxygenation index (PaO2/FIO2) \< 200 mmHg. These parameters must be present for a duration of at least 2 hours.

Exclusion Criteria

  • age \< 18 years
  • decompensated heart insufficiency
  • acute coronary syndrome
  • severe chronic obstructive pulmonary disease
  • advanced tumour conditions with life expectancy \< 6 months
  • chronic dialysis treatment
  • lung transplant patients
  • proven Heparin-induced thrombocytopenia (HIT)
  • morbid obesity (BMI \>) 40
  • Child Class B and C cirrhosis of the liver, acute fulminant hepatic failure

Outcomes

Primary Outcomes

Ventilator free days within 28 days after enrollment

Time Frame: 28 days

Secondary Outcomes

  • hospital mortality, organ-failure free days, pulmonary gas exchange(28 days - 60 days)

Study Sites (1)

Loading locations...

Similar Trials